OFFICIALLY LAUNCHED IN 1999,

 

THE BIOPARK WAS CREATED UNIQUE THROUGH A COMBINATION OF FACTORS

The BioPark was created through a unique combination of political, scientific and social factors resulting in a supportive ecosystem for drug discovery and development across the spectrum of life sciences companies from innovative start-ups through to global players.

HISTORY

  • Origins

    The roots of the BioPark were created by ULB in 1999 when the University founded the Institute for Medical and Molecular Biology (IBMM) in Charleroi, employing 250 researchers, and creating a home for three spin-off companies:

    • Henogen acquired by Novasep in 2009 and still active in the BioPark
    • Delphi Genetics still active in the BioPark
    • Euroscreen renamed into Ogeda and acquired in 2017 by Astellas Pharmaceuticals
    Delphi Genetics Henogen Euroscreen
    Biopark Origins
  • Major Confirmations

    In 2004 and 2011, two additional institutes were created by ULB on the BioPark:

    • The Institute for Medical Immunology (IMI), in partnership with GSK and the Walloon Region.
    • The Center for Medical and Molecular Imaging (CMMI) in partnership with UMONS and with the support of FEDER European funds.
    Biopark Major Confirmations
  • The Incubator

    In 2010, i-Tech Incubator (now BioPark Incubator) was founded on the BioPark to accelerate the creation of start-up companies offering support in the fund-raising process, the creation of business plans, market validation, etc.

    Biopark The Incubator
  • Today

    Today Brussels South Charleroi BioPark encompasses the full biotech innovation chain from target identification to commercial biomanufacturing with the presence of leading research institutes, service providers, fast growing companies, world class venture capital players and international business expertise. This provides a rich environment in which to collaborate and grow businesses. It also creates a dynamic, highly qualified talent pool.

    Biopark Today History
  • A Dedicated Organization

    Since January 2019, the development of Brussels South Charleroi BioPark is coordinated by BioPark Dev SA, the legal entity responsible for coordinating the activities at the BioPark. The main shareholders of BioPark Dev SA are ULB, Sambrinvest, Igretec Charleroi Entreprendre and EEBIC Ventures.

    Biopark A Dedicated Organization